Current Report Filing (8-k)
May 06 2020 - 04:06PM
Edgar (US Regulatory)
0001629137 False 0001629137 2020-05-06
2020-05-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM 8-K
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 6,
2020
_______________________________
Global Blood Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
_______________________________
|
Delaware |
001-37539 |
27-4825712 |
| (State or Other
Jurisdiction of Incorporation) |
(Commission File
Number) |
(I.R.S. Employer
Identification No.) |
181 Oyster Point Blvd.
South San Francisco, California 94080
(Address of Principal Executive Offices) (Zip Code)
(650) 741-7700
(Registrant's telephone number, including area code)
171 Oyster Point Blvd., Suite 300
South San Francisco, CA 94080
(Former name or former address, if changed since last report)
_______________________________
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
| Common Stock, par
value $0.001 per share |
GBT |
The NASDAQ Global
Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company,indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 2.02. Results of
Operations and Financial Condition.
On
May 6, 2020, Global Blood Therapeutics, Inc. reported recent
business progress and its financial results for the first quarter
ended March 31, 2020. The full text of the press release issued in
connection with the announcement is furnished as Exhibit 99.1 to
this Current Report on Form 8-K.
The
information in Item 2.02 of this Form 8-K (including Exhibit 99.1)
shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section, nor shall it be deemed
incorporated by reference under the Securities Act of 1933, as
amended, except as expressly set forth by specific reference in
such a filing.
Item 9.01. Financial
Statements and Exhibits.
SIGNATURE
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
Global
Blood Therapeutics, Inc. |
| |
|
|
| |
|
|
| Date: May 6, 2020 |
By: |
/s/
Jeffrey Farrow |
| |
|
Jeffrey Farrow |
| |
|
Chief Financial Officer
(Principal Financial Officer) |
| |
|
|
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Dec 2020 to Jan 2021
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Jan 2020 to Jan 2021
